Spectrum of mutations in Noonan syndrome and their correlation with phenotypes.

OBJECTIVES To investigate mutation spectrums and their correlations to phenotypes in Noonan syndrome (NS) and NS-related disorders that share functional alterations of the Ras-mitogen-activated protein kinase pathway. STUDY DESIGN Clinical characteristics and genotypes of 10 previously known and 2 candidate genes, SPRY1-4 and SPRED1, were investigated in 59 patients with NS, 17 with cardiofaciocutaneous syndrome, 5 with Costello syndrome, and 2 with LEOPARD syndrome. RESULTS PTPN11 (39.0%), SOS1 (20.3%), RAF1 (6.8%), KRAS (5.1%), and BRAF (1.7%) mutations were identified in NS; BRAF (41.2%), SHOC2 (23.5%), and MEK1 (5.9%) mutations in cardiofaciocutaneous syndrome; and HRAS and PTPN11 mutations in Costello syndrome and LEOPARD syndrome, respectively. No additional mutations were identified in 28.9% of NS and 35.3% of cardiofaciocutaneous syndrome. Functional characterizations of 2 RAF1 novel variants, p.P261T and p.S259T, and one SOS1 variant, p.K170E, showed enhanced activity of Ras-mitogen-activated protein kinase pathway. Normal stature was frequent in SOS1 mutations, hypertrophic cardiomyopathy in RAF1, and developmental delay in RAF1, BRAF, or SHOC2 mutations. CONCLUSIONS By identifying genotype-phenotype correlations, our study highlights the role of molecular genetic testing in the process of differential diagnosis of NS and NS-related disorders. Pathophysiologies that underlie these correlations are needed to be investigated in terms of their effects on Ras-mitogen-activated protein kinase pathway.

[1]  G. Christofori,et al.  Sprouty proteins, masterminds of receptor tyrosine kinase signaling , 2008, Angiogenesis.

[2]  Stefan Mundlos,et al.  Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations , 2006, Journal of Medical Genetics.

[3]  Li Li,et al.  Germline gain-of-function mutations in SOS1 cause Noonan syndrome , 2007, Nature Genetics.

[4]  Wendy Schackwitz,et al.  Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.

[5]  R. Hennekam,et al.  Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies , 2010, Journal of Human Genetics.

[6]  Jodi Gureasko,et al.  Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless , 2010, Proceedings of the National Academy of Sciences.

[7]  W. Kress,et al.  Genotype-phenotype correlations in Noonan syndrome. , 2004, The Journal of pediatrics.

[8]  D. Horn,et al.  SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome , 2007, Journal of Medical Genetics.

[9]  R. Hennekam,et al.  Molecular and clinical characterization of cardio‐facio‐cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome , 2007, American journal of medical genetics. Part A.

[10]  J. Ko,et al.  PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype–phenotype correlation in Korean patients with Noonan syndrome , 2008, Journal of Human Genetics.

[11]  Bruce D Gelb,et al.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.

[12]  Yoichi Matsubara,et al.  Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype–phenotype relationships and overlap with Costello syndrome , 2007, Journal of Medical Genetics.

[13]  R. Hennekam,et al.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.

[14]  Michael J Ackerman,et al.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.

[15]  Y. Matsubara,et al.  The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders , 2008, Human mutation.

[16]  J. Herrington,et al.  Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. , 2000, Molecular endocrinology.

[17]  M. Digilio,et al.  Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype–phenotype correlations , 2009, European Journal of Human Genetics.

[18]  M. Digilio,et al.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. , 2002, American journal of human genetics.

[19]  Ravi Iyengar,et al.  Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair , 2009, Nature Genetics.

[20]  Gabriele Gillessen-Kaesbach,et al.  Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation , 2010, Human mutation.

[21]  W. Reardon,et al.  Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases , 2005, Journal of Medical Genetics.

[22]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[23]  M. Digilio,et al.  Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum , 2009, Human mutation.

[24]  E. Mariman,et al.  Clinical and molecular studies in a large Dutch family with Noonan syndrome. , 1994, American journal of medical genetics.

[25]  D. Horn,et al.  A restricted spectrum of NRAS mutations causes Noonan syndrome , 2010, Nature Genetics.

[26]  D. Horn,et al.  Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome , 2007, Clinical genetics.

[27]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: genetics and pathogenesis. , 2005, Annual review of genomics and human genetics.